等待开盘 06-26 09:30:00 美东时间
+0.270
+2.10%
Keybanc analyst Scott Schoenhaus downgrades ODDITY Tech (NASDAQ:ODD) from Overweight to Sector Weight.
06-03 20:10
Needham analyst Ryan MacDonald reiterates ODDITY Tech (NASDAQ:ODD) from Hold to Hold.
06-03 00:32
Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased
03-13 23:23
ODDITY Tech Ltd. (NASDAQ:ODD) shares are trading lower Wednesday after the company reported fourth-quarter financial results and issued first-quarter sales guidance below estimates.
02-26 00:08
Oddity Tech shares are soaring in extended trading on Wednesday after the company reports better-than-expected results for the third quarter.
2025-11-20 05:57
ODDITY Tech (NASDAQ:ODD) will release its quarterly earnings report on Wednesda...
2025-11-18 22:02
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 药捷安康-B(02617)早盘一度涨超25%,高见217港元,截至发稿,股价上涨19.35%,报199.20港元,成交额7.86亿港元。 据药捷安康官微消息,10月20日,药捷安康宣布,公司在2025年欧洲肿瘤内科学会(ESMO)年会上公开了核心产品替恩戈替尼于胆管癌适应症的最新汇总研究数据。 据悉,替恩戈替尼是一款自主研发、注册性临床阶段的创新多靶点小分子激酶抑制剂,通过靶向肿瘤细胞和改善肿瘤微环境发挥抗肿瘤作用。目前,替恩戈替尼已经在中美两地开展了多项针对胆管癌、前列腺癌、乳腺癌等实体瘤的临床试验,并获得了美国F...
2025-10-22 10:04
(来源:吴说) 1.吴说周精选:李林沈波肖风等推以太坊 DAT、法国银行巨头推出欧元稳定币、SEC 首要任务是代币化与新闻 Top10 本周新闻 Top10...
2025-10-19 22:17
(来源:动脉新医药) 10月16日晚,南京维立志博与Dianthus Therapeutics宣布已就DNTH212(LBL-047)达成独家许可协议。双方达成...
2025-10-17 08:00
机构近期对哪些股票青睐有加? 41股获机构上调评级 机构研报评级上调通常表明市场对相关资产或公司的未来发展持乐观态度,认为其具有较好的增长潜力和投资价值...
2025-10-08 07:37